Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Progressive Corp (PGR) vs Revvity Inc (RVTY) Price & Performance

Progressive CorpTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Progressive Corp vs Revvity Inc — how do they compare? Progressive Corp trades at $204.09 (market cap $119.71B), while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Progressive Corp is far larger — about 9.7× Revvity Inc's market cap, and Progressive Corp pays the higher dividend (6.75%). Which is the better fit depends on your goals.

PGRRVTY
Market Cap
$119.71B$12.33B
Sector
FinancialsTechnology
52-Week High
$252.68$117.75
52-Week Low
$190.40$82.26
Enterprise Value
$127.93B$14.82B
Dividend Yield
6.75%0.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Progressive Corp

Progressive (PGR) trades at $205.9, down 0.99% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and net income rising to $11.3B. Recent Q2 2026 earnings missed expectations at $4.64 EPS, but premiums and investment income remain solid. Analyst consensus is mixed with a $234.56 price target, indicating potential upside from current levels.

The outlook for PGR is cautiously optimistic given its valuation at a P/E of 10.65 and consistent profitability. Key risks include competitive pressures in auto insurance and market volatility. Investment opportunity lies in its scale and data-driven pricing, though near-term performance may hinge on earnings execution and macroeconomic factors affecting the insurance sector.

Revvity Inc

RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.

The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Progressive Corp

Progressive underwrites private and commercial auto insurance and specialty lines

Read more on PGR

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY